Liquid Biopsies – News and Features

Researchers have pioneered a light-based method for analyzing dried blood crystals, enhancing cancer detection. The technique shows 90% accuracy in diagnosing and classifying cancer with less pain and risk compared to traditional methods.

Researchers found a new class of RNA in blood nanoparticles, potentially paving the way for less invasive cancer diagnosis. They used next-generation RNA sequencing and other innovative tools to develop a cost-effective liquid biopsy test.

This article explores how recent advances in nanoscale technology are helping researchers to obtain more data with less hands-on time, vastly increasing what they can study and discover about diseases.

In this article, Asim Siddiqui explores the emerging ability of proteomics to reveal new biomarkers for disease.

UZH and USZ researchers have now further developed an advanced method to analyze liquid biopsies of DNA fragments in the blood. It is fast and practical, without putting much of a strain on patients.

An artificial intelligence-powered method for detecting tumor DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a study led by researchers at Weill Cornell Medicine.

Both genetic and epigenetic sample information is required to get the full picture. Six-base genome sequencing enables this without need of multiple techniques, laborious downstream data processing or data loss, and cancer research is benefiting.

An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.

How can you identify which technique is best suited to your research requirements? In this article, we explore the advantages of qPCR and dPCR, considering specific applications and deliverable metrics to help you choose the right technology to suit your experimental needs.

In this interview, Professor Lawrence Young discusses the current interest in Epstein-Barr virus (EBV) vaccines for combatting multiple sclerosis and his thoughts on the future direction of EBV research.